Role of the Serotonin 2A Receptor in Psilocybin-induced Altered States of Consciousness

PHASE1RecruitingINTERVENTIONAL
Enrollment

16

Participants

Timeline

Start Date

April 21, 2025

Primary Completion Date

August 31, 2026

Study Completion Date

August 31, 2026

Conditions
Healthy
Interventions
DRUG

Ketanserin 40mg plus Psilocybin 40mg

40mg Ketanserin oral will be administered followed by 40mg Psilocybin.

DRUG

40mg Psilocybin

Placebo oral followed by 40mg Psilocybin one hour later.

DRUG

20mg Psilocybin

Placebo oral followed by 20mg Psilocybin one hour later.

DRUG

10mg Psilocybin

Placebo oral followed by 10mg Psilocybin oral one hour later.

DRUG

5mg Psilocybin

Placebo oral followed by 5mg Psilocybin one hour later

OTHER

Placebo

Oral Placebo followed by oral Placebo one hour later

Trial Locations (1)

4056

RECRUITING

Clinical Trial Unit, Basel

All Listed Sponsors
lead

University Hospital, Basel, Switzerland

OTHER